SUTIMLIMAB
Total Payments
$171,795
Transactions
65
Doctors
9
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $171,795 | 65 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $161,361 | 46 | 93.9% |
| Consulting Fee | $5,651 | 2 | 3.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,326 | 12 | 2.5% |
| Food and Beverage | $277.26 | 4 | 0.2% |
| Travel and Lodging | $179.87 | 1 | 0.1% |
Payments by Type
Research
$161,361
46 transactions
General
$10,434
19 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal | BIOVERATIV THERAPEUTICS INC. | $85,969 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusio | BIOVERATIV THERAPEUTICS INC. | $38,939 | 0 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | BIOVERATIV THERAPEUTICS INC. | $25,119 | 2 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfu | BIOVERATIV THERAPEUTICS INC. | $6,579 | 0 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia | BIOVERATIV THERAPEUTICS INC. | $2,250 | 3 |
| A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study) | BIOVERATIV THERAPEUTICS INC. | $1,311 | 2 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) | BIOVERATIV THERAPEUTICS INC. | $1,193 | 3 |
Top Doctors Receiving Payments for SUTIMLIMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Valhalla, NY | $156,279 | 34 |
| , MD | Hematology & Oncology | Washington, DC | $11,685 | 17 |
| , MD DPHIL | Internal Medicine | Boston, MA | $1,967 | 5 |
| , MD | Medical Oncology | Erie, PA | $1,148 | 2 |
| , M.D | Family Medicine | San Antonio, TX | $319.00 | 1 |
| , M.D | Internal Medicine | Washington, DC | $120.00 | 2 |
| , MD | Internal Medicine | Seattle, WA | $78.30 | 1 |
| , M.D., PH.D | Blood Banking & Transfusion Medicine | Baltimore, MD | $75.17 | 1 |
| , M.D | Internal Medicine | San Francisco, CA | $75.17 | 1 |
| , M.D | Hospice and Palliative Medicine | New York, NY | $48.62 | 1 |
Ad
Manufacturing Companies
- BIOVERATIV THERAPEUTICS INC. $171,199
- GENZYME CORPORATION $469.34
- SANOFI-AVENTIS U.S. LLC $126.92
Product Information
- Type Drug
- Total Payments $171,795
- Total Doctors 9
- Transactions 65
About SUTIMLIMAB
SUTIMLIMAB is a drug associated with $171,795 in payments to 9 healthcare providers, recorded across 65 transactions in the CMS Open Payments database. The primary manufacturer is BIOVERATIV THERAPEUTICS INC..
Payment data is available from 2019 to 2019. In 2019, $171,795 was paid across 65 transactions to 9 doctors.
The most common payment nature for SUTIMLIMAB is "Unspecified" ($161,361, 93.9% of total).
SUTIMLIMAB is associated with 7 research studies, including "A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal" ($85,969).